Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2581| Título : | Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats |
| Creador: | Pérez Guille, Beatriz Eugenia |
| Nivel de acceso: | Open access |
| Palabras clave : | Animales Antiinfecciosos - farmacocinética Área Bajo la Curva Cromatografía Líquida de Alta Presión Vida Media Laparotomía Hígado -patología Pruebas de Función Hepática Masculino Metronidazol - farmacocinética Derivación Portocava Quirúrgica Ratas Ratas Consanguíneas Lew Animals Anti-Infective Agents - pharmacokinetics Area Under Curve Chromatography, High Pressure Liquid Half-Life Laparotomy Liver - pathology Liver Function Tests Male Metronidazole - pharmacokinetics Portacaval Shunt, Surgical Rats Rats, Inbred Lew Agentes Antiinfecciosos farmacocinética Metronidazol Anti-Infective Agents pharmacokinetics Metronidazole |
| Descripción : | Portacaval shunts are commonly used to prevent gastroesophageal variceal bleeding secondary to portal hypertension. Ammonia encephalopathy is a common complication and it’s management includes antibiotics such as metronidazole, neomycin and recently, rifaximin. Metronidazole is often used in this context but its pharm acokinetics may be altered in these patients. Compare the pharmacokinetic parameters of two groups of rats, one of them after one year of having undergone mesocaval shunt. A randomized, experimental, prospective study in twenty adult male Lewis rats divided into two groups. The first group underwent mesocaval shunt and the other was the control group. Analyses of the following parameters were performed in both groups: (1) Pharmacokinetics of metronidazole by high-performance liquid chromatography, (2) Transaminase levels and (3) Body and liver weight. Differences between the MCS group and the control group were found for the pharmacokinetic parameters: Cm ax (p = 0.004), Ka (p = 0.009), Ka tl/2 (p = 0.007), Vd (p = 0.01), AUC (p = 0.05) and tmax (p = 0.01) and in ALT levels (p = 0.03) and liver weight (p = 0.00). The results obtained in this experimental model during one year of mesocaval shunt led us to suggest that metronidazole dosage should be decreased, without altering the administration schedule, because the drug levels reached in the mesocaval shunt group caused the animals to behave as if they had been given higher doses. © 2015 Asian Network for Scientific Information. |
| Colaborador(es) u otros Autores: | Villegas-Alvarez F Jimenez-Bravo MA Soriano-Rosales RE Gonzalez-Zamora JF Toledo-Lopez A Camacho-Vieyra GA Guille-Perez A Lares-Asseff I Perez-Guille MG |
| Fecha de publicación : | 2015 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.3923/ijp.2015.143.147 |
| Fuente: | International Journal of Pharmacology 11(2):143 - 147 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2581 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.